19th St. Gallen International Breast Cancer Conference
Key Messages from the Exact Sciences Symposium
Focus on the Pre-Operative Genomic Testing was one of the Key Messages from the Exact Sciences Symposium at St. Gallen 2025. The session also included expert contributions from key opinion leaders where topics like systemic treatment decision-making, neoadjuvant strategies, and patient engagement were shared.
Professor Shani Paluch-Shimon: Optimizing systemic treatment choices using the Oncotype DX BreastRecurrence Score Result pre-operatively
Professor, Stephen Chia MD, FRCP(C): Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DXBreast Recurrence Score Result
Mr Henry Cain: Genomic testing on excision sample vs core biopsy: What we can learn from PreDX?
Patient perspectives: A round table discussion with Prof. Stephen Chia, Prof. Shani Paluch Shimon, and Mr Henry Cain
Previous events video library
-
MDT Live October 2024
MDT Live October 2024
-
MDT Live March 2024
Our 2nd in the series where breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases.
MDT Live March 2024
Our 2nd in the series where breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases. -
[MDT Live March 2024] Case 1 Premenopausal Node Negative Patient
[MDT Live March 2024] Case 1 Premenopausal Node Negative Patient
-
[MDT Live March 2024] Case 2 Older Node Positive Patient
[MDT Live March 2024] Case 2 Older Node Positive Patient
-
[MDT Live March 2024] Case 3 Postmenopausal N1 Patient
[MDT Live March 2024] Case 3 Postmenopausal N1 Patient
-
[MDT Live March 2024] Case 4 Postmenopausal Lobular Patient
[MDT Live March 2024] Case 4 Postmenopausal Lobular Patient
-
[MDT Live March 2024] Case 5 Premenopausal Tubular Patient
[MDT Live March 2024] Case 5 Premenopausal Tubular Patient
-
[MDT Live March 2024] Case 6 Premenopausal T3 Patient
[MDT Live March 2024] Case 6 Premenopausal T3 Patient
-
[MDT Live March 2024] Case 7 Male Breast Cancer Patient
[MDT Live March 2024] Case 7 Male Breast Cancer Patient
-
[MDT Live March 2024] Case 8 Postmenopausal Node Positive Patient
[MDT Live March 2024] Case 8 Postmenopausal Node Positive Patient
-
[MDT Live March 2024] Case 9 Postmenopausal Node-Negative Patient
[MDT Live March 2024] Case 9 Postmenopausal Node-Negative Patient
-
[MDT Live March 2024] Q&A and Close
[MDT Live March 2024] MDT Live March 2024 Q&A and Close
-
[ESMO24] Evolving role of genomic assays in early breast cancerProf. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting
[ESMO24] Evolving role of genomic assays in early breast cancer
Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting -
[ESMO24] Tissue-based genomics to guide adjuvant therapy decisionsProf. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.
[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions
Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients. -
[ESMO24] Introduction to MRD in breast cancerProf. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease.
[ESMO24] Introduction to MRD in breast cancer
Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease. -
[ESMO24] Evolving role of MRD guided decision making in early breast cancerProf. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.
[ESMO24] Evolving role of MRD guided decision making in early breast cancer
Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer. -
[ESMO24] Optimizing the approach to MRD assay developmentRick Baehner provides a topline overview of ongoing research into the development of MRD assays.
[ESMO24] Optimizing the approach to MRD assay development
Rick Baehner provides a topline overview of ongoing research into the development of MRD assays. -
MDT Live 2023
A panel of breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases
MDT Live 2023
A panel of breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases -
Satellite Symposium, St Gallen 2023 - Improve patient care with genomic testing
Patient’s awareness and understanding of genomic testing - Professor Richard Simcock, UKSatellite Symposium, St Gallen 2023 - Improve patient care with genomic testing
Patient’s awareness and understanding of genomic testing - Professor Richard Simcock, UK -
Satellite Symposium, St Gallen 2023 - Improve patient care with genomic testing
Identifying patients for Oncotype DX® testing in my clinical practice - Professor Christos Markopoulos, GreeceSatellite Symposium, St Gallen 2023 - Improve patient care with genomic testing
Identifying patients for Oncotype DX® testing in my clinical practice - Professor Christos Markopoulos, Greece -
The Oncotype DX® Test: Evolution of UK Real World Outcomes Data
Miss Marianne Dillon, Consultant Oncoplastic Breast Surgeon from Swansea Bay University Health Board, Dr Wendy Taylor Consultant Clinical Oncologist at Newcastle upon Tyne Hospitals Trust, Miss P.G. Roy Consultant Oncoplastic and Reconstructive Breast Surgeon at Oxford University Hospitals NHS Trust, and Miss Hirah Rizki Consultant Oncoplastic Breast Surgeon from Imperial College Healthcare NHS Trust.
The Oncotype DX® Test: Evolution of UK Real World Outcomes Data
Miss Marianne Dillon, Consultant Oncoplastic Breast Surgeon from Swansea Bay University Health Board, Dr Wendy Taylor Consultant Clinical Oncologist... -
Follow the evidence to help guide chemotherapy decisions for early breast cancer patients
Dr Richard Simcock, Consultant Clinical Oncologist, Brighton and Sussex University Hospitals NHS Trust, and Dr David Hyams, Medical Director, Eisenhower Medical Center California, present a case study on the evidence to help guide chemotherapy decisions for early breast cancer patients.
Follow the evidence to help guide chemotherapy decisions for early breast cancer patients
Dr Richard Simcock, Consultant Clinical Oncologist, Brighton and Sussex University Hospitals NHS Trust, and Dr David Hyams, Medical Director, -
Clinical utility of multigene assays in early breast cancer: Predictive tests
A presentation by Professor Christos Markopoulos from the University of Athens in Greece talking about the predictive ability of multigene assay in early breast cancer
Clinical utility of multigene assays in early breast cancer: Predictive tests
A presentation by Professor Christos Markopoulos from the University of Athens in Greece talking about the predictive ability of multigene assay... -
Initial RxPONDER results in clinical practice: What will change?
Dr. Joan Albanell from the Hospital del Mar, Spain and and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.
Initial RxPONDER results in clinical practice: What will change?
Dr. Joan Albanell from the Hospital del Mar, Spain and and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER ... -
Initial RxPONDER results in clinical practice: What will change?
Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.
Initial RxPONDER results in clinical practice: What will change?
Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial... -
Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy
Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment decisions in HER2-, HR+, early-stage breast cancer patients.
Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy
Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment... -
The Oncotype DX Breast Recurrence Score assay in clinical practice
Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast Recurrence Score® assay evidence and in particular, the TAILORx landmark trial data.
The Oncotype DX Breast Recurrence Score assay in clinical practice
Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast ...
